Doxycycline benefits in Recurrent Epistaxis in Hereditary hemorrhagic telangiectasia

Doxycycline benefits Recurrent Epistaxis in Hereditary hemorrhagic telangiectasia suggests a new study. However possible benefits of doxycycline  should be interpreted with caution given the overall negative study, says an article published in the Journal of Thrombosis and Hemostasis.

Hereditary hemorrhagic telangiectasia (HHT) is a vascular bleeding illness with visceral arteriovenous malformations and mucocutaneous telangiectasias. Spontaneous recurrent epistaxis is an often debilitating condition. As a result, Justin P. McWilliams and colleagues did this research. A prospective, randomized, placebo-controlled crossover research design was used to determine if doxycycline medication improves epistaxis in HHT.

Between December 2017 and July 2020, twenty-two eligible patients were assigned to one of two trial arms: doxycycline therapy followed by placebo, or vice versa. The primary outcomes compared the severity of epistaxis between treatments. Secondary objectives were changes in quality of life, laboratory indicators of bleeding, and the total amount of monthly blood transfusions or iron infusions. Post-hoc outcomes included the frequency and duration of dripping and gushing epistaxis. A post-hoc longitudinal study looked at the effects of doxycycline over time.